{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T23:58:28Z","timestamp":1775519908200,"version":"3.50.1"},"reference-count":273,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["R01AI145024"],"award-info":[{"award-number":["R01AI145024"]}]},{"name":"NIH","award":["R01AI172607"],"award-info":[{"award-number":["R01AI172607"]}]},{"name":"NIH","award":["R01AI174275"],"award-info":[{"award-number":["R01AI174275"]}]},{"name":"NIH","award":["P30-AI124414"],"award-info":[{"award-number":["P30-AI124414"]}]},{"name":"NIH","award":["5T32GM149364-02"],"award-info":[{"award-number":["5T32GM149364-02"]}]},{"name":"NIH","award":["T32AI007501"],"award-info":[{"award-number":["T32AI007501"]}]},{"name":"Einstein-Rockefeller-CUNY Center for AIDS Research","award":["R01AI145024"],"award-info":[{"award-number":["R01AI145024"]}]},{"name":"Einstein-Rockefeller-CUNY Center for AIDS Research","award":["R01AI172607"],"award-info":[{"award-number":["R01AI172607"]}]},{"name":"Einstein-Rockefeller-CUNY Center for AIDS Research","award":["R01AI174275"],"award-info":[{"award-number":["R01AI174275"]}]},{"name":"Einstein-Rockefeller-CUNY Center for AIDS Research","award":["P30-AI124414"],"award-info":[{"award-number":["P30-AI124414"]}]},{"name":"Einstein-Rockefeller-CUNY Center for AIDS Research","award":["5T32GM149364-02"],"award-info":[{"award-number":["5T32GM149364-02"]}]},{"name":"Einstein-Rockefeller-CUNY Center for AIDS Research","award":["T32AI007501"],"award-info":[{"award-number":["T32AI007501"]}]},{"name":"T32","award":["R01AI145024"],"award-info":[{"award-number":["R01AI145024"]}]},{"name":"T32","award":["R01AI172607"],"award-info":[{"award-number":["R01AI172607"]}]},{"name":"T32","award":["R01AI174275"],"award-info":[{"award-number":["R01AI174275"]}]},{"name":"T32","award":["P30-AI124414"],"award-info":[{"award-number":["P30-AI124414"]}]},{"name":"T32","award":["5T32GM149364-02"],"award-info":[{"award-number":["5T32GM149364-02"]}]},{"name":"T32","award":["T32AI007501"],"award-info":[{"award-number":["T32AI007501"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Although combination antiretroviral therapy (ART) has been a landmark achievement for the treatment of human immunodeficiency virus (HIV), an HIV cure has remained elusive. Elimination of latent HIV reservoirs that persist throughout HIV infection is the most challenging barrier to an HIV cure. The progressive HIV infection is marked by the increasing size and diversity of latent HIV reservoirs until an effective immune response is mobilized, which can control but not eliminate HIV infection. The stalemate between HIV replication and the immune response is manifested by the establishment of a viral set point. ART initiation during the early stage limits HIV reservoir development, preserves immune function, improves the quality of life, and may lead to ART-free viral remission in a few people living with HIV (PLWH). However, for the overwhelming majority of PLWH, early ART initiation alone does not cure HIV, and lifelong ART is needed to sustain viral suppression. A critical area of research is focused on determining whether HIV could be functionally cured if additional treatments are provided alongside early ART. Several HIV interventions including Block and Lock, Shock and Kill, broadly neutralizing antibody (bNAb) therapy, adoptive CD8+ T cell therapy, and gene therapy have demonstrated delayed viral rebound and\/or viral remission in animal models and\/or some PLWH. Whether or not their application during early infection can improve the success of HIV remission is less studied. Herein, we review the current state of clinical and investigative HIV interventions and discuss their potential to improve the likelihood of post-treatment remission if initiated during early infection.<\/jats:p>","DOI":"10.3390\/v16101588","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T07:39:52Z","timestamp":1728459592000},"page":"1588","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Interventions during Early Infection: Opening a Window for an HIV Cure?"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7983-5833","authenticated-orcid":false,"given":"Christopher R.","family":"Hiner","sequence":"first","affiliation":[{"name":"Department of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April L.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0543-6025","authenticated-orcid":false,"given":"Harris","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA"},{"name":"Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1126\/science.1079027","article-title":"Historical essay. A history of HIV discovery","volume":"298","author":"Montagnier","year":"2002","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1126\/science.1078050","article-title":"Historical essay. The early years of HIV\/AIDS","volume":"298","author":"Gallo","year":"2002","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","article-title":"Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: A collaborative analysis of cohort studies","volume":"10","author":"Trickey","year":"2023","journal-title":"Lancet HIV"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.1256304","article-title":"HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection","volume":"345","author":"Wagner","year":"2014","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.1254194","article-title":"HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells","volume":"345","author":"Maldarelli","year":"2014","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1073\/pnas.1522675113","article-title":"Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo","volume":"113","author":"Simonetti","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e128432","DOI":"10.1172\/jci.insight.128432","article-title":"Clones of infected cells arise early in HIV-infected individuals","volume":"4","author":"Coffin","year":"2019","journal-title":"JCI Insight"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation","volume":"360","author":"Hutter","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Saez-Cirion, A., Mamez, A.C., Avettand-Fenoel, V., Nabergoj, M., Passaes, C., Thoueille, P., Decosterd, L., Hentzien, M., Perdomo-Celis, F., and Salgado, M. (2024). Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells. Nat. Med.","DOI":"10.1038\/s41591-024-03277-z"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","article-title":"HIV-1 remission following CCR5Delta32\/Delta32 haematopoietic stem-cell transplantation","volume":"568","author":"Gupta","year":"2019","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41591-023-02213-x","article-title":"In-depth virological and immunological characterization of HIV-1 cure after CCR5Delta32\/Delta32 allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Jensen","year":"2023","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(24)00090-0","article-title":"Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: A prospective observational cohort study","volume":"11","author":"Salgado","year":"2024","journal-title":"Lancet HIV"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/COH.0000000000000751","article-title":"Elite and posttreatment controllers, two facets of HIV control","volume":"17","author":"Mastrangelo","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41586-020-2651-8","article-title":"Distinct viral reservoirs in individuals with spontaneous control of HIV-1","volume":"585","author":"Jiang","year":"2020","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Saez-Cirion, A., Bacchus, C., Hocqueloux, L., Avettand-Fenoel, V., Girault, I., Lecuroux, C., Potard, V., Versmisse, P., Melard, A., and Prazuck, T. (2013). Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003211"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/infdis\/jiy479","article-title":"The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies","volume":"218","author":"Namazi","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_17","unstructured":"Wood, B. (2024, June 18). Acute and Recent HIV Infection. National HIV Curriculum, Updated 9 October 2023, Available online: https:\/\/www.hiv.uw.edu\/go\/screening-diagnosis\/acute-recent-early-hiv\/core-concept\/all."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/infdis\/jir699","article-title":"The setpoint study (ACTG A5217): Effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals","volume":"205","author":"Hogan","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.15585\/mmwr.mm6811e1","article-title":"Vital Signs: HIV Transmission Along the Continuum of Care\u2014United States, 2016","volume":"68","author":"Li","year":"2019","journal-title":"Morb. Mortal. Wkly. Rep. (MMWR)"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1086\/506616","article-title":"A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection","volume":"194","author":"Hecht","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection","volume":"373","author":"Group","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/QAD.0000000000001417","article-title":"Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"31","author":"Lifson","year":"2017","journal-title":"AIDS"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1016\/S2666-5247(21)00010-0","article-title":"Long-term effects of early antiretroviral initiation on HIV reservoir markers: A longitudinal analysis of the MERLIN clinical study","volume":"2","author":"Massanella","year":"2021","journal-title":"Lancet Microbe"},{"key":"ref_24","unstructured":"(2024, June 20). HIV Treatment: The Basics. NIH.gov, Available online: https:\/\/hivinfo.nih.gov\/understanding-hiv\/fact-sheets\/hiv-treatment-basics#:~:text=The%20treatment%20for%20HIV%20is,medicines%20as%20soon%20as%20possible."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41591-018-0026-6","article-title":"Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection","volume":"24","author":"Colby","year":"2018","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Henrich, T.J., Hatano, H., Bacon, O., Hogan, L.E., Rutishauser, R., Hill, A., Kearney, M.F., Anderson, E.M., Buchbinder, S.P., and Cohen, S.E. (2017). HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Med., 14.","DOI":"10.1371\/journal.pmed.1002417"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Su, H., Cheng, Y., Sravanam, S., Mathews, S., Gorantla, S., Poluektova, L.Y., Dash, P.K., and Gendelman, H.E. (2019). Immune Activations and Viral Tissue Compartmentalization During Progressive HIV-1 Infection of Humanized Mice. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00340"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/s41467-019-10366-y","article-title":"Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice","volume":"10","author":"Dash","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1126\/science.adf7966","article-title":"Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques","volume":"383","author":"Lim","year":"2024","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","article-title":"Combination anti-HIV antibodies provide sustained virological suppression","volume":"606","author":"Sneller","year":"2022","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","article-title":"Prolonged viral suppression with anti-HIV-1 antibody therapy","volume":"606","author":"Gaebler","year":"2022","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/s41591-023-02547-6","article-title":"Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: The randomized phase 2a TITAN trial","volume":"29","author":"Gunst","year":"2023","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","article-title":"Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: A phase 1b\/2a, randomized trial","volume":"28","author":"Gunst","year":"2022","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Su, H., Sravanam, S., Gorantla, S., Kaminski, R., Khalili, K., Poluektova, L., Gendelman, H.E., and Dash, P.K. (2020). Amplification of Replication Competent HIV-1 by Adoptive Transfer of Human Cells From Infected Humanized Mice. Front. Cell. Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.00038"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"eaav3491","DOI":"10.1126\/scitranslmed.aav3491","article-title":"Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection","volume":"12","author":"Leyre","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_37","unstructured":"(2024, June 25). Post-Exposure Prophylaxis (PEP). Updated 6 February 2024, Available online: https:\/\/hivinfo.NIH.gov\/home-page."},{"key":"ref_38","first-page":"343","article-title":"The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption","volume":"30","author":"Li","year":"2016","journal-title":"AIDS"},{"key":"ref_39","unstructured":"UNAIDS (2023). Global HIV & AIDS Statistics\u2014Fact Sheet, UNAIDS."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJMoa1302976","article-title":"Absence of detectable HIV-1 viremia after treatment cessation in an infant","volume":"369","author":"Persaud","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_41","first-page":"393","article-title":"French teenager healthy 12 years after ceasing HIV treatment","volume":"523","year":"2015","journal-title":"Nature"},{"key":"ref_42","unstructured":"Persaud, D.C.A., Nelson, B.S., Jao, J., Capparelli, E., Costello, D., Tierney, C., Kekitiinwa, A.R., Nematadzira, T., Njau, B.N., and Moye, J. (2024, January 3\u20136). ART-Free HIV-1 Remission in Very Early Treated Children: Results from IMPAACT P1115. Proceedings of the CROI 2024, Denver, CO, USA."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/17843286.2020.1770413","article-title":"Benefits of antiretroviral therapy initiation during acute HIV infection","volume":"77","author":"Rutsaert","year":"2022","journal-title":"Acta Clin. Belg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41467-023-44389-3","article-title":"Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8(+) T-cells","volume":"15","author":"Passaes","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1097\/QAD.0000000000001195","article-title":"Polyfunctional HIV-specific T cells in Post-Treatment Controllers","volume":"30","author":"Samri","year":"2016","journal-title":"AIDS"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Berendam, S.J., Nelson, A.N., Yagnik, B., Goswami, R., Styles, T.M., Neja, M.A., Phan, C.T., Dankwa, S., Byrd, A.U., and Garrido, C. (2022). Challenges and Opportunities of Therapies Targeting Early Life Immunity for Pediatric HIV Cure. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.885272"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/COH.0000000000000857","article-title":"Pediatric immunotherapy and HIV control","volume":"19","author":"Chinunga","year":"2024","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nri.2016.19","article-title":"Paediatric HIV infection: The potential for cure","volume":"16","author":"Goulder","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7120","DOI":"10.1128\/JVI.77.12.7120-7123.2003","article-title":"Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection","volume":"77","author":"Richardson","year":"2003","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"eaax7350","DOI":"10.1126\/scitranslmed.aax7350","article-title":"Early antiretroviral therapy in neonates with HIV-1 infection restricts viral reservoir size and induces a distinct innate immune profile","volume":"11","author":"Maddali","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4049\/jimmunol.1900856","article-title":"Impact of Early Antiretroviral Therapy Initiation on HIV-Specific CD4 and CD8 T Cell Function in Perinatally Infected Children","volume":"204","author":"Rinaldi","year":"2020","journal-title":"J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biomaterials.2017.10.023","article-title":"Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles","volume":"151","author":"Zhou","year":"2018","journal-title":"Biomaterials"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41563-020-0674-z","article-title":"A year-long extended release nanoformulated cabotegravir prodrug","volume":"19","author":"Kulkarni","year":"2020","journal-title":"Nat. Mater."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41467-018-02885-x","article-title":"Creation of a long-acting nanoformulated dolutegravir","volume":"9","author":"Sillman","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"115009","DOI":"10.1016\/j.addr.2023.115009","article-title":"Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection","volume":"200","author":"Sillman","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: A randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: A randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"8","author":"Jaeger","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection","volume":"386","author":"DeJesus","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3018(22)00291-0","article-title":"Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: A randomised, open-label, active-controlled, phase 2 trial","volume":"10","author":"Gupta","year":"2023","journal-title":"Lancet HIV"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-Yearly Lenacapavir or Daily F\/TAF for HIV Prevention in Cisgender Women","volume":"391","author":"Bekker","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e25408","DOI":"10.1002\/jia2.25408","article-title":"Acceptability of a long-acting injectable HIV prevention product among US and African women: Findings from a phase 2 clinical Trial (HPTN 076)","volume":"22","author":"Tolley","year":"2019","journal-title":"J. Int. AIDS Soc."},{"key":"ref_64","unstructured":"Rana, A.I.B.Y., Zheng, L., Sieczkarski, S., Lake, J.E., Fichtenbaum, C.J., Morton, T., Fox, L., Wannamaker, P., Castillo-Mancilla, J.R., and Vandermeulen, K. (2024, January 3\u20136). Long-Acting Injectable CAB\/RPV is Superior to Oral ART in PWH with Adherence Challenges: ACTG A5359. Proceedings of the CROI 2024, Denver, CO, USA."},{"key":"ref_65","unstructured":"Gaur, A.C.E., Baltrusaitis, K., Marzinke, M., Harrington, C.M., McCoig, C., Crauwels, H., Townley, E., Moye, J., Buisson, S., and Violari, A. (2024, January 3\u20136). Long-Acting Cabotegravir plus Rilpivirine in Adolescents with HIV: Week 24 IMPAACT 2017(MOCHA) Study. Proceedings of the CROI 2024, Denver, CO, USA."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ebiom.2019.06.020","article-title":"Deep latency: A new insight into a functional HIV cure","volume":"45","author":"Elsheikh","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.chom.2012.05.016","article-title":"An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription","volume":"12","author":"Mousseau","year":"2012","journal-title":"Cell Host Microbe"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.celrep.2017.09.080","article-title":"In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a \u201cBlock-and-Lock\u201d Strategy for HIV-1 Treatment","volume":"21","author":"Kessing","year":"2017","journal-title":"Cell Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"8280","DOI":"10.1096\/fj.201801165R","article-title":"The Tat inhibitor didehydro-cortistatin A suppresses SIV replication and reactivation","volume":"33","author":"Mediouni","year":"2019","journal-title":"FASEB J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2017.08.013","article-title":"Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription","volume":"146","author":"Hayashi","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e0092323","DOI":"10.1128\/jvi.00923-23","article-title":"CDK8 inhibitors antagonize HIV-1 reactivation and promote provirus latency in T cells","volume":"97","author":"Horvath","year":"2023","journal-title":"J. Virol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e0163022","DOI":"10.1128\/jvi.01630-22","article-title":"A Camptothetin Analog, Topotecan, Promotes HIV Latency via Interference with HIV Transcription and RNA Splicing","volume":"97","author":"Mukim","year":"2023","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Jean, M.J., Hayashi, T., Huang, H., Brennan, J., Simpson, S., Purmal, A., Gurova, K., Keefer, M.C., Kobie, J.J., and Santoso, N.G. (2017). Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.02007"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e0047021","DOI":"10.1128\/AAC.00470-21","article-title":"A New Small-Molecule Compound, Q308, Silences Latent HIV-1 Provirus by Suppressing Tat- and FACT-Mediated Transcription","volume":"65","author":"Zhou","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1172\/JCI120633","article-title":"Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV","volume":"129","author":"Niu","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Nguyen, K., Dobrowolski, C., Shukla, M., Cho, W.K., Luttge, B., and Karn, J. (2021). Inhibition of the H3K27 demethylase UTX enhances the epigenetic silencing of HIV proviruses and induces HIV-1 DNA hypermethylation but fails to permanently block HIV reactivation. PLoS Pathog., 17.","DOI":"10.1101\/2021.08.02.454353"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e01247-20","DOI":"10.1128\/JVI.01247-20","article-title":"The XPB Subunit of the TFIIH Complex Plays a Critical Role in HIV-1 Transcription and XPB Inhibition by Spironolactone Prevents HIV-1 Reactivation from Latency","volume":"95","author":"Mori","year":"2021","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"10332","DOI":"10.1074\/jbc.M116.717538","article-title":"Inhibition of Heat Shock Protein 90 Prevents HIV Rebound","volume":"291","author":"Joshi","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"E1528","DOI":"10.1073\/pnas.1320178111","article-title":"Heat shock protein 90 controls HIV-1 reactivation from latency","volume":"111","author":"Anderson","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"154855","DOI":"10.1016\/j.phymed.2023.154855","article-title":"Wogonin inhibits latent HIV-1 reactivation by downregulating histone crotonylation","volume":"116","author":"Zhang","year":"2023","journal-title":"Phytomedicine"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"de Armas, L.R., Gavegnano, C., Pallikkuth, S., Rinaldi, S., Pan, L., Battivelli, E., Verdin, E., Younis, R.T., Pahwa, R., and Williams, S.L. (2021). The Effect of JAK1\/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.720697"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/cid\/ciab212","article-title":"Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults with Human Immunodeficiency Virus","volume":"74","author":"Marconi","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e01744-18","DOI":"10.1128\/AAC.01744-18","article-title":"Inhibitors of Signaling Pathways That Block Reversal of HIV-1 Latency","volume":"63","author":"Vargas","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e0006723","DOI":"10.1128\/aac.00067-23","article-title":"Ponatinib Represses Latent HIV-1 by Inhibiting AKT-mTOR","volume":"67","author":"Huang","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"100341","DOI":"10.1016\/j.jve.2023.100341","article-title":"Sulforaphane prevents the reactivation of HIV-1 by suppressing NF\u03baB signaling","volume":"9","author":"Jamal","year":"2023","journal-title":"J. Virus Erad."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"001877","DOI":"10.1099\/jgv.0.001877","article-title":"Inhibition of salt inducible kinases reduces rhythmic HIV-1 replication and reactivation from latency","volume":"104","author":"Borrmann","year":"2023","journal-title":"J. Gen. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12977-018-0451-0","article-title":"RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency","volume":"15","author":"Ledger","year":"2018","journal-title":"Retrovirology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/mt.2014.29","article-title":"An HIV-encoded antisense long noncoding RNA epigenetically regulates viral transcription","volume":"22","author":"Saayman","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"11730","DOI":"10.1038\/ncomms11730","article-title":"Long noncoding RNA NRON contributes to HIV-1 latency by specifically inducing tat protein degradation","volume":"7","author":"Li","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Olson, A., Basukala, B., Lee, S., Gagne, M., Wong, W.W., and Henderson, A.J. (2020). Targeted Chromatinization and Repression of HIV-1 Provirus Transcription with Repurposed CRISPR\/Cas9. Viruses, 12.","DOI":"10.3390\/v12101154"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12977-022-00600-9","article-title":"Repression of HIV-1 reactivation mediated by CRISPR\/dCas9-KRAB in lymphoid and myeloid cell models","volume":"19","author":"Bomfim","year":"2022","journal-title":"Retrovirology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1002\/cmdc.202100422","article-title":"Development of 7SK snRNA Mimics That Inhibit HIV Transcription","volume":"16","author":"Yamayoshi","year":"2021","journal-title":"ChemMedChem"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e01769-19","DOI":"10.1128\/mBio.01769-19","article-title":"Strong In Vivo Inhibition of HIV-1 Replication by Nullbasic, a Tat Mutant","volume":"10","author":"Jin","year":"2019","journal-title":"mBio"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Leoz, M., Kukanja, P., Luo, Z., Huang, F., Cary, D.C., Peterlin, B.M., and Fujinaga, K. (2018). HEXIM1-Tat chimera inhibits HIV-1 replication. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007402"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e13314","DOI":"10.15252\/emmm.202013314","article-title":"Antioxidant nanozyme counteracts HIV-1 by modulating intracellular redox potential","volume":"13","author":"Singh","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/COH.0000000000000844","article-title":"New latency-promoting agents for a block-and-lock functional cure strategy","volume":"19","author":"Pellaers","year":"2024","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Vargas, B., and Sluis-Cremer, N. (2022). Toward a Functional Cure for HIV-1 Infection: The Block and Lock Therapeutic Approach. Front. Virol., 2.","DOI":"10.3389\/fviro.2022.917941"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Moranguinho, I., and Valente, S.T. (2020). Block-And-Lock: New Horizons for a Cure for HIV-1. Viruses, 12.","DOI":"10.3390\/v12121443"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"7801","DOI":"10.1093\/nar\/gkaa536","article-title":"The chromatin landscape at the HIV-1 provirus integration site determines viral expression","volume":"48","author":"Vansant","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nsmb.3328","article-title":"Position effects influence HIV latency reversal","volume":"24","author":"Chen","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e02328-20","DOI":"10.1128\/AAC.02328-20","article-title":"GS-9822, a preclinical LEDGIN candidate, displays a block-and-lock phenotype in cell culture","volume":"65","author":"Bruggemans","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ebiom.2016.04.039","article-title":"LEDGIN-mediated Inhibition of Integrase-LEDGF\/p75 Interaction Reduces Reactivation of Residual Latent HIV","volume":"8","author":"Vranckx","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Janssens, J., De Wit, F., Parveen, N., and Debyser, Z. (2022). Single-Cell Imaging Shows That the Transcriptional State of the HIV-1 Provirus and Its Reactivation Potential Depend on the Integration Site. mBio, 13.","DOI":"10.1128\/mbio.00007-22"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1038\/s41564-024-01816-5","article-title":"Silencing the transcriptionally active HIV reservoir to improve treatment outcomes","volume":"9","author":"Prigann","year":"2024","journal-title":"Nat. Microbiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/1570162043484915","article-title":"Can HIV be Cured? Mechanisms of HIV persistence and strategies to combat it","volume":"2","author":"Hamer","year":"2004","journal-title":"Curr. HIV Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/487439a","article-title":"Shock and kill","volume":"487","author":"Deeks","year":"2012","journal-title":"Nature"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Brogdon, J., Ziani, W., Wang, X., Veazey, R.S., and Xu, H. (2016). In vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation. Sci. Rep., 6.","DOI":"10.1038\/srep39032"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"10688","DOI":"10.1073\/pnas.1919408117","article-title":"Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window","volume":"117","author":"Sloane","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1097\/QAD.0000000000001064","article-title":"Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy","volume":"30","author":"Barbas","year":"2016","journal-title":"AIDS"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Divsalar, D.N., Simoben, C.V., Schonhofer, C., Richard, K., Sippl, W., Ntie-Kang, F., and Tietjen, I. (2020). Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00905"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e92901","DOI":"10.1172\/jci.insight.92901","article-title":"HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal","volume":"2","author":"Wu","year":"2017","journal-title":"JCI Insight"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1089\/aid.2021.0195","article-title":"Isoform-Selective Versus Nonselective Histone Deacetylase Inhibitors in HIV Latency Reversal","volume":"38","author":"Evelyn","year":"2022","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: A phase 1\/2, single group, clinical trial","volume":"1","author":"Rasmussen","year":"2014","journal-title":"Lancet HIV"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"16538","DOI":"10.1074\/jbc.M110.103531","article-title":"Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294","volume":"285","author":"Imai","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12977-020-00547-9","article-title":"Modulation of BRD4 in HIV epigenetic regulation: Implications for finding an HIV cure","volume":"18","author":"Alamer","year":"2021","journal-title":"Retrovirology"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Huertas, M.R., Jim\u00e9nez-Tormo, L., Madrid-Elena, N., Guti\u00e9rrez, C., Rodr\u00edguez-Mora, S., Coiras, M., Alcam\u00ed, J., and Moreno, S. (2017). The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-02634-y"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-020-1951-3","article-title":"Systemic HIV and SIV latency reversal via non-canonical NF-\u03baB signalling in vivo","volume":"578","author":"Nixon","year":"2020","journal-title":"Nature"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"100037","DOI":"10.1016\/j.xcrm.2020.100037","article-title":"Pharmacological Activation of Non-canonical NF-\u03baB Signaling Activates Latent HIV-1 Reservoirs In Vivo","volume":"1","author":"Pache","year":"2020","journal-title":"Cell Rep. Med."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Martinsen, J.T., Gunst, J.D., H\u00f8jen, J.F., Tolstrup, M., and S\u00f8gaard, O.S. (2020). The Use of Toll-like Receptor Agonists in HIV-1 Cure Strategies. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.01112"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Macedo, A.B., Novis, C.L., and Bosque, A. (2019). Targeting Cellular and Tissue HIV Reservoirs with Toll-like Receptor Agonists. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02450"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e0081621","DOI":"10.1128\/JVI.00816-21","article-title":"TLR1\/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4+ T Cells","volume":"95","author":"Duan","year":"2021","journal-title":"J. Virol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Ait-Ammar, A., Kula, A., Darcis, G., Verdikt, R., De Wit, S., Gautier, V., Mallon, P.W.G., Marcello, A., Rohr, O., and Van Lint, C. (2019). Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.03060"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11904-020-00540-z","article-title":"Latency Reversal 2.0: Giving the Immune System a Seat at the Table","volume":"18","author":"Singh","year":"2021","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Bricker, K.M., Chahroudi, A., and Mavigner, M. (2021). New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models. Viruses, 13.","DOI":"10.3390\/v13081560"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Matsuda, K., and Maeda, K. (2024). HIV Reservoirs and Treatment Strategies toward Curing HIV Infection. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052621"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev-virology-091919-103029","article-title":"The Current Status of Latency Reversing Agents for HIV-1 Remission","volume":"8","author":"Rodari","year":"2021","journal-title":"Annu. Rev. Virol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Liang, T., Wu, Z., Li, Y., Li, C., Zhao, K., Qiao, X., Duan, H., Zhang, X., Liu, S., and Xi, B. (2022). A synthetic resveratrol analog termed Q205 reactivates latent HIV-1 through activation of P-TEFb. Biochem. Pharmacol., 197.","DOI":"10.1016\/j.bcp.2021.114901"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1021\/acsinfecdis.3c00218","article-title":"Bcl-2 Antagonist Obatoclax Reactivates Latent HIV-1 via the NF-\u03baB Pathway and Induces Latent Reservoir Cell Apoptosis in Latently Infected Cells","volume":"9","author":"Zhou","year":"2023","journal-title":"ACS Infect. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/011570162X248488230926045852","article-title":"Novel Aptamers for the Reactivation of Latent HIV","volume":"21","author":"Serumula","year":"2023","journal-title":"Curr. HIV Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bbrc.2022.12.024","article-title":"4-phenylquinoline-8-amine induces HIV-1 reactivation and apoptosis in latently HIV-1 infected cells","volume":"641","author":"Kitamura","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Sanz, M., Weideman, A.M.K., Ward, A.R., Clohosey, M.L., Garcia-Recio, S., Selitsky, S.R., Mann, B.T., Iannone, M.A., Whitworth, C.P., and Chitrakar, A. (2023). Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1219250"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"100004","DOI":"10.1016\/j.jve.2020.100004","article-title":"A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection","volume":"6","author":"Kroon","year":"2020","journal-title":"J. Virus Erad."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2666-5247(21)00239-1","article-title":"Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): A randomised, open-label, phase 2A trial","volume":"3","author":"Gruell","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0140-6736(05)67098-5","article-title":"Depletion of latent HIV-1 infection in vivo: A proof-of-concept study","volume":"366","author":"Lehrman","year":"2005","journal-title":"Lancet"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/QAD.0b013e3282fd6df4","article-title":"Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells","volume":"22","author":"Archin","year":"2008","journal-title":"Aids"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature11286","article-title":"Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy","volume":"487","author":"Archin","year":"2012","journal-title":"Nature"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1310\/hct1306-301","article-title":"Design and implementation of a randomized crossover study of valproic acid and antiretroviral therapy to reduce the HIV reservoir","volume":"13","author":"Routy","year":"2012","journal-title":"HIV Clin. Trials"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/infdis\/jiu155","article-title":"HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat","volume":"210","author":"Archin","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Wei, D.G., Chiang, V., Fyne, E., Balakrishnan, M., Barnes, T., Graupe, M., Hesselgesser, J., Irrinki, A., Murry, J.P., and Stepan, G. (2014). Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004071"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/infdis\/jiaa777","article-title":"A Phase 1\/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons with HIV-1 on Suppressive Antiretroviral Therapy","volume":"224","author":"McMahon","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1016\/S2352-3018(15)00226-X","article-title":"Short-term administration of disulfiram for reversal of latent HIV infection: A phase 2 dose-escalation study","volume":"2","author":"Elliott","year":"2015","journal-title":"Lancet HIV"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Ros\u00e1s-Umbert, M., Ruiz-Riol, M., Fern\u00e1ndez, M.A., Marszalek, M., Coll, P., Manzardo, C., Cede\u00f1o, S., Mir\u00f3, J.M., Clotet, B., and Hanke, T. (2020). In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00418"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Mu, W., Patankar, V., Kitchen, S., and Zhen, A. (2024). Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection. Viruses, 16.","DOI":"10.3390\/v16020219"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Ruiz, A., Blanch-Lombarte, O., Jimenez-Moyano, E., Ouchi, D., Mothe, B., Pe\u00f1a, R., Galvez, C., Genesc\u00e0, M., Martinez-Picado, J., and Goulder, P. (2018). Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.03162"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Kopycinski, J., Yang, H., Hancock, G., Pace, M., Kim, E., Frater, J., St\u00f6hr, W., Hanke, T., Fidler, S., and Dorrell, L. (2023). Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-42888-3"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/21645515.2019.1666957","article-title":"T cell-based strategies for HIV-1 vaccines","volume":"16","author":"Korber","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/COH.0000000000000824","article-title":"Generating and measuring effective vaccine-elicited HIV-specific CD8 + T cell responses","volume":"18","author":"Borgo","year":"2023","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Howard, J.N., and Bosque, A. (2023). IL-15 and N-803 for HIV Cure Approaches. Viruses, 15.","DOI":"10.3390\/v15091912"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4049\/jimmunol.180.1.350","article-title":"IL-15 treatment during acute simian immunodeficiency virus (SIV) infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8+ T cell responses","volume":"180","author":"Mueller","year":"2008","journal-title":"J. Immunol."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Covino, D.A., Desimio, M.G., and Doria, M. (2022). Impact of IL-15 and latency reversing agent combinations in the reactivation and NK cell-mediated suppression of the HIV reservoir. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-23010-5"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e0037222","DOI":"10.1128\/jvi.00372-22","article-title":"The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation","volume":"96","author":"Macedo","year":"2022","journal-title":"J. Virol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Baron, M., Souli\u00e9, C., Lavol\u00e9, A., Assoumou, L., Abbar, B., Fouquet, B., Rousseau, A., Veyri, M., Samri, A., and Makinson, A. (2022). Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer. Cells, 11.","DOI":"10.3390\/cells11061015"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41467-019-08798-7","article-title":"PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals","volume":"10","author":"Fromentin","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"ofad694","DOI":"10.1093\/ofid\/ofad694","article-title":"Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons with Human Immunodeficiency Virus on Antiretroviral Therapy","volume":"11","author":"Gay","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41467-021-27647-0","article-title":"Latency reversal plus natural killer cells diminish HIV reservoir in vivo","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/infdis\/jiaa223","article-title":"Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy","volume":"223","author":"Zhou","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e01632-24","DOI":"10.1128\/mbio.01632-24","article-title":"Analysis of the effect of HDAC inhibitors on the formation of the HIV reservoir","volume":"15","author":"Ling","year":"2024","journal-title":"mBio"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.chembiol.2023.11.009","article-title":"A histone deacetylase network regulates epigenetic reprogramming and viral silencing in HIV-infected cells","volume":"30","author":"Peterson","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Jones, R.B., O\u2019Connor, R., Mueller, S., Foley, M., Szeto, G.L., Karel, D., Lichterfeld, M., Kovacs, C., Ostrowski, M.A., and Trocha, A. (2014). Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004287"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Boucau, J., Das, J., Joshi, N., and Le Gall, S. (2020). Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008442"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-020-1946-0","article-title":"Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8+ cells","volume":"578","author":"McBrien","year":"2020","journal-title":"Nature"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eclinm.2019.05.009","article-title":"Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)","volume":"11","author":"Mothe","year":"2019","journal-title":"EClinicalMedicine"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent progress in broadly neutralizing antibodies to HIV","volume":"19","author":"Sok","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2013.03.018","article-title":"Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization","volume":"153","author":"Klein","year":"2013","journal-title":"Cell"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"105788","DOI":"10.1016\/j.antiviral.2023.105788","article-title":"Next-generation bNAbs for HIV-1 cure strategies","volume":"222","author":"Schriek","year":"2024","journal-title":"Antivir. Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1021\/acsomega.2c07933","article-title":"An Overview of Human Anti-HIV-1 Neutralizing Antibodies against Diverse Epitopes of HIV-1","volume":"8","author":"Kumar","year":"2023","journal-title":"ACS Omega"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e00152-22","DOI":"10.1128\/cmr.00152-22","article-title":"Broadly neutralizing antibodies for HIV prevention: A comprehensive review and future perspectives","volume":"37","author":"Mahomed","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1084\/jem.20161765","article-title":"Progress toward active or passive HIV-1 vaccination","volume":"214","author":"Escolano","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1128\/JVI.02339-09","article-title":"Inhibition of In Vivo HIV Infection in Humanized Mice by Gene Therapy of Human Hematopoietic Stem Cells with a Lentiviral Vector Encoding a Broadly Neutralizing Anti-HIV Antibody","volume":"84","author":"Joseph","year":"2010","journal-title":"J. Virol."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Hsu, D.C., Mellors, J.W., and Vasan, S. (2021). Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.710044"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Carrillo, J., Clotet, B., and Blanco, J. (2018). Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02429"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature11604","article-title":"HIV therapy by a combination of broadly neutralizing antibodies in humanized mice","volume":"492","author":"Klein","year":"2012","journal-title":"Nature"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"18754","DOI":"10.1073\/pnas.2008236117","article-title":"Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody","volume":"117","author":"Asokan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e00498-17","DOI":"10.1128\/JVI.00498-17","article-title":"Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys","volume":"91","author":"Julg","year":"2017","journal-title":"J. Virol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature12746","article-title":"Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia","volume":"503","author":"Shingai","year":"2013","journal-title":"Nature"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"110199","DOI":"10.1016\/j.celrep.2021.110199","article-title":"Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys","volume":"38","author":"Pegu","year":"2022","journal-title":"Cell Rep."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","article-title":"Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice","volume":"158","author":"Lu","year":"2014","journal-title":"Cell"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1126\/science.aaf1279","article-title":"Enhanced clearance of HIV-1\u2013infected cells by broadly neutralizing antibodies against HIV-1 in vivo","volume":"352","author":"Lu","year":"2016","journal-title":"Science"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"e02051-18","DOI":"10.1128\/JVI.02051-18","article-title":"Establishment of a Novel Humanized Mouse Model To Investigate In Vivo Activation and Depletion of Patient-Derived HIV Latent Reservoirs","volume":"93","author":"Flerin","year":"2019","journal-title":"J. Virol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"18002","DOI":"10.1073\/pnas.2008190117","article-title":"Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti\u2013HIV-1 IgG1 antibodies in vivo","volume":"117","author":"Wang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41591-019-0747-1","article-title":"Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity","volume":"26","author":"Niessl","year":"2020","journal-title":"Nat. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature21435","article-title":"Early antibody therapy can induce long-lasting immunity to SHIV","volume":"543","author":"Nishimura","year":"2017","journal-title":"Nature"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1038\/s41467-022-34171-2","article-title":"Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity","volume":"13","author":"Gunst","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/COH.0000000000000555","article-title":"Vaccinal effect of HIV-1 antibody therapy","volume":"14","author":"Pelegrin","year":"2019","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"16538","DOI":"10.1073\/pnas.1315295110","article-title":"HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice","volume":"110","author":"Horwitz","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1084\/jem.20190287","article-title":"HIV-specific humoral immune responses by CRISPR\/Cas9-edited B cells","volume":"216","author":"Hartweger","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1038\/s41467-020-19649-1","article-title":"Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion","volume":"11","author":"Nahmad","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1038\/s41467-020-19650-8","article-title":"Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells","volume":"11","author":"Huang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41587-022-01328-9","article-title":"In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice","volume":"40","author":"Nahmad","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41551-024-01179-6","article-title":"In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies","volume":"8","author":"Yin","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"eaax4380","DOI":"10.1126\/science.aax4380","article-title":"A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses","volume":"366","author":"Steichen","year":"2019","journal-title":"Science"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41577-022-00753-w","article-title":"Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies","volume":"23","author":"Haynes","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S1473-3099(23)00481-4","article-title":"Vaccinating people living with HIV: A fast track to preventive and therapeutic HIV vaccines","volume":"24","author":"Trkola","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"eadd6502","DOI":"10.1126\/science.add6502","article-title":"Vaccination induces HIV broadly neutralizing antibody precursors in humans","volume":"378","author":"Leggat","year":"2022","journal-title":"Science"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"eadn0622","DOI":"10.1126\/sciimmunol.adn0622","article-title":"mRNA-LNP prime boost evolves precursors toward VRC01-like broadly neutralizing antibodies in preclinical humanized mouse models","volume":"9","author":"Wang","year":"2024","journal-title":"Sci. Immunol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"eadk0582","DOI":"10.1126\/science.adk0582","article-title":"mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies","volume":"384","author":"Xie","year":"2024","journal-title":"Science"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"eadn0223","DOI":"10.1126\/scitranslmed.adn0223","article-title":"Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice","volume":"16","author":"Cottrell","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/mt.2015.70","article-title":"Engineering T Cells to Functionally Cure HIV-1 Infection","volume":"23","author":"Leibman","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"e17481","DOI":"10.1016\/j.heliyon.2023.e17481","article-title":"Recent advances in CD8+ T cell-based immune therapies for HIV cure","volume":"9","author":"Arenas","year":"2023","journal-title":"Heliyon"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/COH.0000000000000693","article-title":"Immunological effector mechanisms in HIV-1 elite controllers","volume":"16","author":"Hartana","year":"2021","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/hiv.13021","article-title":"The role of CD8 T cells in controlling HIV beyond the antigen-specific face","volume":"21","author":"Zhang","year":"2020","journal-title":"HIV Med."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-020-0274-9","article-title":"CD8+ T cells in HIV control, cure and prevention","volume":"20","author":"Collins","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood.V90.6.2196","article-title":"Safety of Autologous, Ex Vivo-Expanded Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T-Lymphocyte Infusion in HIV-Infected Patients","volume":"90","author":"Lieberman","year":"1997","journal-title":"Blood"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nm0296-216","article-title":"T\u2013cell mediated rejection of gene\u2013modified HIV\u2013specific cytotoxic T lymphocytes in HIV\u2013infected patients","volume":"2","author":"Riddell","year":"1996","journal-title":"Nat. Med."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nm0495-330","article-title":"Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression","volume":"1","author":"Koenig","year":"1995","journal-title":"Nat. Med."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1128\/JVI.01812-07","article-title":"Lentiviral Vectors Encoding Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Receptor Genes Efficiently Convert Peripheral Blood CD8 T Lymphocytes into Cytotoxic T Lymphocytes with Potent In Vitro and In Vivo HIV-1-Specific Inhibitory Activity","volume":"82","author":"Joseph","year":"2008","journal-title":"J. Virol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/nm.1779","article-title":"Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor","volume":"14","author":"Molloy","year":"2008","journal-title":"Nat. Med."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-1-0716-3862-0_20","article-title":"Generation of Anti-HIV CAR-T Cells for Preclinical Research","volume":"2807","author":"Su","year":"2024","journal-title":"Methods Mol. Biol."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Jadlowsky, J., Baiduc, C., Klattenhoff, A.W., Chen, Z., Bennett, A.D., Pumphrey, N.J., Jakobsen, B.K., and Riley, J.L. (2023). Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells. PLoS Pathog., 19.","DOI":"10.1371\/journal.ppat.1011853"},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Campos-Gonzalez, G., Martinez-Picado, J., Velasco-Hernandez, T., and Salgado, M. (2023). Opportunities for CAR-T Cell Immunotherapy in HIV Cure. Viruses, 15.","DOI":"10.3390\/v15030789"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"York, J., Gowrishankar, K., Micklethwaite, K., Palmer, S., Cunningham, A.L., and Nasr, N. (2022). Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir via CAR T Cell Immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.873701"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/COH.0000000000000858","article-title":"Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission","volume":"19","author":"Su","year":"2024","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V84.9.2878.2878","article-title":"Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors","volume":"84","author":"Roberts","year":"1994","journal-title":"Blood"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"11478","DOI":"10.1073\/pnas.94.21.11478","article-title":"Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor\u2009T\u2009cells","volume":"94","author":"Yang","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4\u03b6 gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus\u2013infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"key":"ref_220","first-page":"467","article-title":"Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection","volume":"96","author":"Walker","year":"2000","journal-title":"Blood"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/mthe.2002.0611","article-title":"A Phase II Randomized Study of HIV-Specific T-Cell Gene Therapy in Subjects with Undetectable Plasma Viremia on Combination Antiretroviral Therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol. Ther."},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Alnefaie, A., Albogami, S., Asiri, Y., Ahmad, T., Alotaibi, S.S., Al-Sanea, M.M., and Althobaiti, H. (2022). Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.797440"},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Leibman, R.S., Richardson, M.W., Ellebrecht, C.T., Maldini, C.R., Glover, J.A., Secreto, A.J., Kulikovskaya, I., Lacey, S.F., Akkina, S.R., and Yi, Y. (2017). Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006613"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"eaav5685","DOI":"10.1126\/scitranslmed.aav5685","article-title":"Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model","volume":"11","author":"Bardhi","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1128\/JVI.00805-16","article-title":"HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies","volume":"90","author":"Ali","year":"2016","journal-title":"J. Virol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ymthe.2016.12.023","article-title":"Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells","volume":"25","author":"Hale","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"e150211","DOI":"10.1172\/JCI150211","article-title":"Broadly neutralizing antibody\u2013derived CAR T cells reduce viral reservoir in individuals infected with HIV-1","volume":"131","author":"Liu","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"e161698","DOI":"10.1172\/jci.insight.161698","article-title":"In vivo killing of primary HIV-infected cells by peripheral-injected early memory-enriched anti-HIV duoCAR T cells","volume":"7","author":"Ray","year":"2022","journal-title":"JCI Insight"},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Jiang, Z., Liang, H., Pan, H., Liang, Y., Wang, H., Yang, X., Lu, P., Zhang, X., Yang, J., and Zhang, D. (2021). HIV-1-Specific CAR-T Cells with Cell-Intrinsic PD-1 Checkpoint Blockade Enhance Anti-HIV Efficacy in vivo. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.684016"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.virs.2023.01.003","article-title":"Allogeneic gene-edited HIV-specific CAR-T cells secreting PD-1 blocking scFv enhance specific cytotoxic activity against HIV Env(+) cells invivo","volume":"38","author":"Pan","year":"2023","journal-title":"Virol. Sin."},{"key":"ref_231","doi-asserted-by":"crossref","unstructured":"Kranz, E., Kuhlmann, C.J., Chan, J., Kim, P.Y., Chen, I.S.Y., and Kamata, M. (2022). Efficient derivation of chimeric-antigen receptor-modified TSCM cells. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.877682"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ymthe.2024.02.026","article-title":"Stem cell-derived CAR T cells show greater persistence, trafficking, and viral control compared to ex vivo transduced CAR T cells","volume":"32","author":"Carrillo","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"e136648","DOI":"10.1172\/jci.insight.136648","article-title":"TCF-1 regulates HIV-specific CD8+ T cell expansion capacity","volume":"6","author":"Rutishauser","year":"2021","journal-title":"JCI Insight"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.3390\/v5123119","article-title":"Gene Therapy Strategies for HIV\/AIDS: Preclinical Modeling in Humanized Mice","volume":"5","author":"Bennett","year":"2013","journal-title":"Viruses"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood-2016-01-678144","article-title":"The clinical applications of genome editing in HIV","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00439-016-1678-2","article-title":"TALEN gene editing takes aim on HIV","volume":"135","author":"Benjamin","year":"2016","journal-title":"Hum. Genet."},{"key":"ref_237","first-page":"58263","article-title":"The Potential Use of the CRISPR-Cas System for HIV-1 Gene Therapy","volume":"2019","author":"Medeiros","year":"2019","journal-title":"Int. J. Genom."},{"key":"ref_238","doi-asserted-by":"crossref","unstructured":"Xiao, Q., Guo, D., and Chen, S. (2019). Application of CRISPR\/Cas9-Based Gene Editing in HIV-1\/AIDS Therapy. Front. Cell. Infect. Microbiol., 9.","DOI":"10.3389\/fcimb.2019.00069"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"109741","DOI":"10.1016\/j.clim.2023.109741","article-title":"Antiretrovirals to CCR5 CRISPR\/Cas9 gene editing\u2014A paradigm shift chasing an HIV cure","volume":"255","author":"Khan","year":"2023","journal-title":"Clin. Immunol."},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Mohamed, H., Gurrola, T., Berman, R., Collins, M., Sariyer, I.K., Nonnemacher, M.R., and Wigdahl, B. (2022). Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.816515"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"30603","DOI":"10.1074\/jbc.272.49.30603","article-title":"Mechanism of Transdominant Inhibition of CCR5-mediated HIV-1 Infection by ccr5\u039432","volume":"272","author":"Benkirane","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/382722a0","article-title":"Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene","volume":"382","author":"Samson","year":"1996","journal-title":"Nature"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1196-1240","article-title":"The role of a mutant CCR5 allele in HIV-1 transmission and disease progression","volume":"2","author":"Huang","year":"1996","journal-title":"Nat. Med."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2010-09-309591","article-title":"Evidence for the cure of HIV infection by CCR5\u039432\/\u039432 stem cell transplantation","volume":"117","author":"Allers","year":"2011","journal-title":"Blood"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nbt1410","article-title":"Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases","volume":"26","author":"Perez","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nbt.1663","article-title":"Human hematopoietic stem\/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo","volume":"28","author":"Holt","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/hum.2012.172","article-title":"Efficient Clinical Scale Gene Modification via Zinc Finger Nuclease\u2013Targeted Disruption of the HIV Co-receptor CCR5","volume":"24","author":"Maier","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"e144486","DOI":"10.1172\/JCI144486","article-title":"CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication","volume":"131","author":"Tebas","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41434-021-00271-9","article-title":"Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application","volume":"28","author":"Schwarze","year":"2021","journal-title":"Gene Ther."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41434-021-00259-5","article-title":"Automated production of CCR5-negative CD4+-T cells in a GMP-compatible, clinical scale for treatment of HIV-positive patients","volume":"28","author":"Schwarze","year":"2021","journal-title":"Gene Ther."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1099\/vir.0.000139","article-title":"Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR\/Cas9","volume":"96","author":"Li","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.omtn.2018.05.012","article-title":"Inducing CCR5\u039432\/\u039432 Homozygotes in the Human Jurkat CD4+ Cell Line and Primary CD4+ Cells by CRISPR-Cas9 Genome-Editing Technology","volume":"12","author":"Qi","year":"2018","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_254","doi-asserted-by":"crossref","unstructured":"Liu, Z., Liang, J., Chen, S., Wang, K., Liu, X., Liu, B., Xia, Y., Guo, M., Zhang, X., and Sun, G. (2020). Genome editing of CCR5 by AsCpf1 renders CD4+T cells resistance to HIV-1 infection. Cell Biosci., 10.","DOI":"10.1186\/s13578-020-00444-w"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.ymthe.2017.04.027","article-title":"CRISPR\/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem\/Progenitor Cells Confers HIV-1 Resistance In Vivo","volume":"25","author":"Xu","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_256","doi-asserted-by":"crossref","unstructured":"Hou, P., Chen, S., Wang, S., Yu, X., Chen, Y., Jiang, M., Zhuang, K., Ho, W., Hou, W., and Huang, J. (2015). Genome editing of CXCR4 by CRISPR\/cas9 confers cells resistant to HIV-1 infection. Sci. Rep., 5.","DOI":"10.1038\/srep15577"},{"key":"ref_257","doi-asserted-by":"crossref","unstructured":"Liu, Z., Chen, S., Jin, X., Wang, Q., Yang, K., Li, C., Xiao, Q., Hou, P., Liu, S., and Wu, S. (2017). Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4+ T cells from HIV-1 infection. Cell Biosci., 7.","DOI":"10.1186\/s13578-017-0174-2"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.exphem.2006.04.002","article-title":"Mutual, reciprocal SDF-1\/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD\/SCID chimeric mice","volume":"34","author":"Dar","year":"2006","journal-title":"Exp. Hematol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/382635a0","article-title":"Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF\/SDF-1","volume":"382","author":"Nagasawa","year":"1996","journal-title":"Nature"},{"key":"ref_260","doi-asserted-by":"crossref","unstructured":"Hussein, M., Molina, M.A., Berkhout, B., and Herrera-Carrillo, E. (2023). A CRISPR-Cas Cure for HIV\/AIDS. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021563"},{"key":"ref_261","doi-asserted-by":"crossref","unstructured":"Ebina, H., Misawa, N., Kanemura, Y., and Koyanagi, Y. (2013). Harnessing the CRISPR\/Cas9 system to disrupt latent HIV-1 provirus. Sci. Rep., 3.","DOI":"10.1038\/srep02510"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12977-015-0150-z","article-title":"The CRISPR\/Cas9 system inactivates latent HIV-1 proviral DNA","volume":"12","author":"Zhu","year":"2015","journal-title":"Retrovirology"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1038\/ncomms7413","article-title":"Use of the CRISPR\/Cas9 system as an intracellular defense against HIV-1 infection in human cells","volume":"6","author":"Liao","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_264","doi-asserted-by":"crossref","unstructured":"Kaminski, R., Chen, Y., Fischer, T., Tedaldi, E., Napoli, A., Zhang, Y., Karn, J., Hu, W., and Khalili, K. (2016). Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR\/Cas9 Gene Editing. Sci. Rep., 6.","DOI":"10.1038\/srep22555"},{"key":"ref_265","doi-asserted-by":"crossref","unstructured":"Lebbink, R.J., De Jong, D.C.M., Wolters, F., Kruse, E.M., Van Ham, P.M., Wiertz, E.J.H.J., and Nijhuis, M. (2017). A combinational CRISPR\/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. Sci. Rep., 7.","DOI":"10.1038\/srep41968"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"e2217887120","DOI":"10.1073\/pnas.2217887120","article-title":"CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice","volume":"120","author":"Dash","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1146\/annurev.immunol.17.1.657","article-title":"CHEMOKINE RECEPTORS AS HIV-1 CORECEPTORS: Roles in Viral Entry, Tropism, and Disease","volume":"17","author":"Berger","year":"1999","journal-title":"Annu. Rev. Immunol."},{"key":"ref_268","doi-asserted-by":"crossref","unstructured":"Darcis, G., Binda, C.S., Klaver, B., Herrera-Carrillo, E., Berkhout, B., and Das, A.T. (2019). The Impact of HIV-1 Genetic Diversity on CRISPR-Cas9 Antiviral Activity and Viral Escape. Viruses, 11.","DOI":"10.3390\/v11030255"},{"key":"ref_269","doi-asserted-by":"crossref","unstructured":"Sullivan, N.T., Allen, A.G., Atkins, A.J., Chung, C.-H., Dampier, W., Nonnemacher, M.R., and Wigdahl, B. (2020). Designing Safer CRISPR\/Cas9 Therapeutics for HIV: Defining Factors That Regulate and Technologies Used to Detect Off-Target Editing. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.01872"},{"key":"ref_270","doi-asserted-by":"crossref","unstructured":"Atkins, A., Chung, C.-H., Allen, A.G., Dampier, W., Gurrola, T.E., Sariyer, I.K., Nonnemacher, M.R., and Wigdahl, B. (2021). Off-Target Analysis in Gene Editing and Applications for Clinical Translation of CRISPR\/Cas9 in HIV-1 Therapy. Front. Genome Ed., 3.","DOI":"10.3389\/fgeed.2021.673022"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1089\/aid.2014.0224","article-title":"I am the Berlin patient: A personal reflection","volume":"31","author":"Brown","year":"2015","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_272","doi-asserted-by":"crossref","unstructured":"Dash, P.K., Kevadiya, B.D., Su, H., Banoub, M.G., and Gendelman, H.E. (2020). Pathways towards human immunodeficiency virus elimination. EBioMedicine, 53.","DOI":"10.1016\/j.ebiom.2020.102667"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41579-024-01010-8","article-title":"Immune targeting of HIV-1 reservoir cells: A path to elimination strategies and cure","volume":"22","author":"Bone","year":"2024","journal-title":"Nat. Rev. Microbiol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/10\/1588\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:09:54Z","timestamp":1760112594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/10\/1588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":273,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["v16101588"],"URL":"https:\/\/doi.org\/10.3390\/v16101588","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]}}}